课题基金 / 基金详情

Antigenetic analysis of human amniotic epithelium and its clinical application to tumor markers

Antigenetic analysis of human amniotic epithelium and its clinical application to tumor markers
人羊膜上皮抗原分析及其在肿瘤标志物中的临床应用
批准号:
62570742
负责人:
INABA Noriyuki
金额:
$1.41万
依托单位国家:
日本
项目类别:
Grant-in-Aid for General Scientific Research (C)
财政年份:
1987
资助国家:
日本
项目状态:
已结题
起止时间:
1987 至 1988

项目摘要

项目成果

INABA Noriyuki的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. The reactivity of monoclonal antibodies against human cancer cell lines on human amniotic epi-thelium cell lines: In our laboratories 22 murine monoclonal antibodies have been established by using 10 human cancer cell lines, namely PC-1(pulmonary squamouse cell ca),PC-10(pulmonary squamouse cell ca),PC-9(pulmonary adenoca),HEp-2(pharyngeal squamouse cell ca),TE-9(esophageal squamouse cell ca),KATO-III(gastric ring cell ca),COLON CA(colonic adenoca),HEK(choleduct ade-noca),PANC-1(pancreatic adnoca) and ZR75-1(breast adenoca). With use of an ELISA, these all mo-noclonal antibodies were found to react with either and/or both of human culture cells of amnio-tic epithelium (FL and WISH).2. Immunohistochemical investigation of human tumor markers in human placentae: By using ABC method, the localization of CA125.CA130,CA19-9,CA50,KM0 1 and TAC 41 were investigated in human early and term placentae. These all tumor markers recognized by mo-noclonal antibodies against human cancer cell lines were clearly localized in the amniotic epi-thelium. Thus, these tumor markers could be designated " amniotic epithlium-related antigens (AEA)".3. AEA levels in maternal blood, amniotic fluid and umbilical blood: The concentration of CA125(RIA),CA130(RIA),CA19-9(EIA),CA50(EIA) and TAC 41(RPHA) was measured in maternal blood(prior to and just after delivery),amniotic fluid and paired blood from umbilical artery and vein in 10 preagnant cases. The levels of these 5 AEAs were strikingly elevated in amniotic fluid,while the levels remained within normal limits in maternal and umbilical blood. These all find-ings indicate clear common antigenecity between amniotic epithelium and cancers. In addition, these results may facilitate to develop new tumor markers.
期刊论文(34)
专著(0)
科研奖励(0)
会议论文
稲葉憲之: Oncologr & Chemotherapy.
Noriyuki Inaba:肿瘤学家和化疗。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
稲葉憲之,深沢一雄,上村凡尋 他: 基礎と臨床. 21. 4203-4207 (1987)
Noriyuki Inaba、Kazuo Fukasawa、Bonhiro Uemura 等:基础和临床研究。21. 4203-4207 (1987)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
稲葉憲之: 日本外科連合学会誌. 18. 33-36 (1989)
Noriyuki Inaba:日本外科联合会杂志 18. 33-36 (1989)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Itahashi, Koshirou: "Immunohistochemical study of tissue polypeptide antigen (TPA) and cancer antigen 125(CA125) in human and cynomolgus monkey placenta, umbilical cord and decidua" Arch Gynecol Obstet. 243. 145-155 (1988)
Itahashi, Koshirou:“人类和食蟹猴胎盘、脐带和蜕膜中组织多肽抗原 (TPA) 和癌抗原 125 (CA125) 的免疫组织化学研究”Arch Gynecol Obstet。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
31
    Risk factors for HCV vertical transmission -with special reference to maternal HCV/HIV double carrier-state-
    • 批准号:
      07457607
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $1.6万
    • 财政年份:
      1995
    • 负责人:
      INABA Noriyuki
    • 依托单位:
    An Investigation on The Modes of HCV Infection -Possible Materno-infantile and Sexual Transmission of HCV-
    • 批准号:
      03454392
    • 项目类别:
      Grant-in-Aid for General Scientific Research (B)
    • 资助金额:
      $2.05万
    • 财政年份:
      1991
    • 负责人:
      INABA Noriyuki
    • 依托单位:
    A new approach to the diagnosis of Endometrial Carcinoma - P-450HFLa and PP 4 -
    • 批准号:
      01570918
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $1.34万
    • 财政年份:
      1989
    • 负责人:
      INABA Noriyuki
    • 依托单位:
    The Study on Materno-Infantile Vertical Transmission of ATLV in Human and Monkey
    • 批准号:
      60570768
    • 项目类别:
      Grant-in-Aid for General Scientific Research (C)
    • 资助金额:
      $1.22万
    • 财政年份:
      1985
    • 负责人:
      INABA Noriyuki
    • 依托单位: